Allogreffe de cellules souches hématopoïétiques à partir d’un donneur haplo-identique*
Bulletin de l'Académie Nationale de Médecine, ISSN: 0001-4079, Vol: 206, Issue: 8, Page: 961-965
2022
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Mentions1
- News Mentions1
- 1
Most Recent News
Research Conducted at Sorbonne University Has Updated Our Knowledge about Cell Transplants (Hematopoietic Stem Cell Transplantation From Haplo-identical Donors)
2022 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Daily -- Investigators discuss new findings in Transplant Medicine - Cell
Review Description
L’allogreffe de cellules souches hématopoïétiques (allo-CSH) est une thérapeutique curative pour de nombreuses hémopathies malignes et non malignes. L’identification d’un donneur de cellules souches compatible a toujours représenté une barrière majeure à l’accès à l’allo-CSH. L’avènement des allogreffes dites haplo-identiques représente un véritable tournant dans ce domaine dans la mesure où cela ouvre des perspectives de traitement à la majorité des malades en attente d’une allo-CSH en l’absence d’un donneur HLA compatible ou non familial. Cette revue résume les développements les plus récents dans ce domaine et leurs perspectives. Allogeneic hematopoietic stem cell transplantation is a curative therapy for many malignant and non-malignant blood diseases. Identifying a compatible stem cell donor has always been a major barrier to perform allogeneic transplantation. The advent of so-called haplo-identical allografts represents a real turning point in this field, as it opens up treatment prospects for the majority of patients in the absence of an HLA compatible donor. This review summarizes the most recent developments in this field and their prospects.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0001407922002400; http://dx.doi.org/10.1016/j.banm.2022.07.028; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85136191221&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S0001407922002400; https://dx.doi.org/10.1016/j.banm.2022.07.028
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know